EPS for Gladstone Capital (GLAD) Expected At $0.21; Histogenics (HSGX) Had 5 Analysts Last Week

November 4, 2017 - By Vivian Currie

Among 6 analysts covering Histogenics Corp (NASDAQ:HSGX), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Histogenics Corp had 13 analyst reports since August 27, 2015 according to SRatingsIntel. The rating was initiated by H.C. Wainwright with “Buy” on Monday, December 19. The stock of Histogenics Corp (NASDAQ:HSGX) has “Buy” rating given on Friday, November 13 by Canaccord Genuity. The firm has “Buy” rating given on Friday, November 13 by Needham. Needham maintained it with “Buy” rating and $8 target in Monday, September 19 report. The company was downgraded on Thursday, August 27 by Zacks. The firm has “Neutral” rating given on Friday, November 13 by BTIG Research. The firm has “Buy” rating given on Thursday, November 2 by H.C. Wainwright. On Wednesday, September 7 the stock rating was downgraded by William Blair to “Market Perform”. As per Monday, October 16, the company rating was maintained by Canaccord Genuity. BTIG Research upgraded Histogenics Corp (NASDAQ:HSGX) on Friday, August 12 to “Buy” rating. See Histogenics Corp (NASDAQ:HSGX) latest ratings:

02/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $3.5 Maintain
16/10/2017 Broker: Canaccord Genuity Rating: Buy New Target: $4.0 Maintain
11/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $3.5000
27/06/2017 Broker: Canaccord Genuity Rating: Buy New Target: $4.0000

Analysts expect Gladstone Capital Corporation (NASDAQ:GLAD) to report $0.21 EPS on November, 20.They anticipate $0.00 EPS change or 0.00% from last quarter’s $0.21 EPS. GLAD’s profit would be $5.48M giving it 11.63 P/E if the $0.21 EPS is correct. After having $0.21 EPS previously, Gladstone Capital Corporation’s analysts see 0.00% EPS growth. The stock increased 0.10% or $0.01 on November 3, reaching $9.77. About 85,939 shares traded. Gladstone Capital Corporation (NASDAQ:GLAD) has risen 40.20% since November 4, 2016 and is uptrending. It has outperformed by 23.50% the S&P500.

Investors sentiment increased to 1.67 in Q2 2017. Its up 0.38, from 1.29 in 2017Q1. It is positive, as 6 investors sold Gladstone Capital Corporation shares while 12 reduced holdings. 13 funds opened positions while 17 raised stakes. 3.26 million shares or 9.87% more from 2.97 million shares in 2017Q1 were reported. 19,176 were accumulated by Hl Fincl Ltd Liability Corporation. Wfg Advsrs L P has 11,980 shares for 0.03% of their portfolio. 738 are owned by Comml Bank Of America De. Bard Associates has 29,350 shares for 0.13% of their portfolio. Janney Montgomery Scott, Pennsylvania-based fund reported 25,840 shares. 79,531 are owned by Jpmorgan Chase. 61,669 were accumulated by Legal General Group Public Limited. Da Davidson, a Montana-based fund reported 9,167 shares. Koshinski Asset Mgmt reported 0% of its portfolio in Gladstone Capital Corporation (NASDAQ:GLAD). 221,397 are held by Van Eck Associates Corp. Howe Rusling Inc owns 575 shares. Asset Mngmt reported 171,702 shares. Manufacturers Life The owns 0% invested in Gladstone Capital Corporation (NASDAQ:GLAD) for 1,547 shares. Royal Fincl Bank Of Canada reported 19,922 shares stake. Arrowstreet Partnership owns 55,147 shares for 0% of their portfolio.

Gladstone Capital Corporation is a closed-end, non-diversified management investment company, operating as a business development firm . The company has market cap of $255.15 million. The objectives of the Company are to achieve and grow current income by investing in debt securities of established businesses that it believes will provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness and make distributions to stockholders that grow over time, and to provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that it believes can grow over time to permit it to sell its equity investments for capital gains. It has a 7.26 P/E ratio. The Firm is focused on investing in lower middle-market companies in the United States.

Among 3 analysts covering Gladstone Capital (NASDAQ:GLAD), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Gladstone Capital had 4 analyst reports since August 24, 2015 according to SRatingsIntel. Vetr downgraded Gladstone Capital Corporation (NASDAQ:GLAD) on Monday, August 24 to “Buy” rating. The firm earned “Hold” rating on Wednesday, September 27 by Wedbush. The stock of Gladstone Capital Corporation (NASDAQ:GLAD) earned “Hold” rating by Cantor Fitzgerald on Tuesday, September 1. Hilliard Lyons upgraded the shares of GLAD in report on Friday, May 5 to “Neutral” rating.

The stock increased 0.47% or $0.01 on November 3, reaching $2.15. About 22,597 shares traded. Histogenics Corp (NASDAQ:HSGX) has declined 7.61% since November 4, 2016 and is downtrending. It has underperformed by 24.31% the S&P500.